Clinical trials: Toxicity, Drug, open to volunteers
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Neuropathy, Cancer
Daily Hand-Held Vibration Therapy
The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity of CIPN in the hands.
- Conditions
- Neuropathy, Cancer, Chemotherapeutic Drug - Induced Nephropathy, Chemotherapeutic Toxicity
- Trial name
- NCT04207437
- Testing
- Vibration therapy
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Indiana University
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Lymphoma, Physical Exercise
Effects of Exercise Training in Survivors of Lymphoma
This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and…
- Conditions
- Lymphoma, Physical Exercise, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- LYMfit (NCT06270667)
- Testing
- Aerobic Exercise, Combined Aerobic and Resistance Exercise
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Norwegian School of Sport Sciences
Breast Cancer, Drug-Related Side Effects and Adverse Reactions
Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients
This study is a multicenter randomized controlled trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer receiving cyclin-dependent kinase (CDK) inhibitor therapy.
- Conditions
- Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Chemotherapy Toxicity, Treatment Adherence
- Trial name
- NCT07524829
- Testing
- Structured Telenursing Follow-up, Standard Nursing Care
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Azienda Sanitaria Locale di Asti
Breast Cancer, Metastatic Breast Cancer
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
The metabolism of anticancer drugs is influenced by genetic variants that affect their bioavailability and toxicity. In the case of antibody-drug conjugates (ADCs), such as sacituzumab-govitecan (SG), trastuzumab-deruxtecan…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetic Variant
- Trial name
- NCT07582887
- Testing
- Sacituzumab Govitecan, Trastuzumab deruxtecan, Datopotamab Deruxtecan
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Ofloxacin, Bone and Joint Infection
Ofloxacin Concentration-toxicity Relationship in the Elderly
Ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to sensible staphylococcus strains. However, in the elderly, inter-individual variability of the pharmacokinetics may reduce the efficacy…
- Conditions
- Ofloxacin, Bone and Joint Infection, Therapeutic Drug Monitoring, Adverse Drug Reactions
- Trial name
- ROSCO (NCT04496024)
- Testing
- ofloxacin, questionnaire, Ofloxacin Serum concentration
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Myocarditis, Cardiomyopathies
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) might induce high grade immune-related adverse events (irAEs) involving the cardio-vascular system.
- Conditions
- Myocarditis, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases
- Trial name
- JOCARDITE (NCT04294771)
- Testing
- ICI
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Geriatric Assessment, Adjuvant Drug Therapy
Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening
Older breast cancer patients should not be categorically excluded from adjuvant therapies, including the recommended CDK4/6 inhibitors (CDK4/6i) administered in combination with endocrine therapy.
- Conditions
- Geriatric Assessment, Adjuvant Drug Therapy, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Trial name
- FUTURE (NCT07273357)
- Where
- 5 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Jönköping County
Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer.
- Conditions
- Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity, Chemo-brain, Cancer
- Trial name
- MyBrain (NCT05840575)
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multidisciplinary Consultation Program, Adherence to Oral Anticancer Treatment
Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment
Oncology management has changed dramatically over the last decade with the approval and rapid adoption of newly targeted oral oncology medications.
- Conditions
- Multidisciplinary Consultation Program, Adherence to Oral Anticancer Treatment, Drug Related Toxicity, Securing Medication Management
- Trial name
- IMPAM (NCT04797143)
- Testing
- multidisciplinary consultation program
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Charcoal, Decontamination, Poisoning
Activated CHARcoal in Poisoned Patient - Pilot Trial
The goal of this clinical pilot trial is to determine the feasibility of the clinical trial. Then the large-scale CHARPP will be conducted in order to determine the efficacity of activated charcoal as a treatment for acute…
- Trial name
- CHARPP-Pilot (NCT05471479)
- Testing
- Activated Charcoal, No activated charcoal
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Laval University
Melanoma Stage IV, Melanoma Stage III
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
- Conditions
- Melanoma Stage IV, Melanoma Stage III, Immunotherapy, Toxicity, Drug
- Trial name
- NCT05652673
- Testing
- nivolumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Anthracycline-induced Cardiac Toxicity, Breast Cancer
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based…
- Conditions
- Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
- Trial name
- ROSUBREAST (NCT07254221)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 7 sites in Iran
- Volunteers
- 400 people
- Sponsor
- Shiraz University of Medical Sciences
Pancreatic Cancer, Skin Toxicities
A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer
The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach…
- Trial name
- NCT07895498
- Testing
- Minocycline, Hypochlorous Acid, Hydrocortison cream
- Where
- 7 sites in United States
- Volunteers
- 122 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mediastinal Lymphoma, Hodgkin Lymphoma
Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation
Malignant anterior mediastinal tumors essentially include lymphomas and thymomas. The location of mediastinum is anatomically close to several critical organs such as heart, lung, and breasts, which might be affected meaningfully…
- Conditions
- Mediastinal Lymphoma, Hodgkin Lymphoma, Non Hodgkin Lymphoma
- Trial name
- NCT03969693
- Testing
- Standard treatment protocol with combined chemoradiation
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Chang Gung Memorial Hospital
Prostate Cancer, Radiation Toxicity
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment.
- Conditions
- Prostate Cancer, Radiation Toxicity, Urinary Complication
- Trial name
- NCT05530655
- Testing
- Lisinopril Tablets
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Cardiotoxicity, HER2/Neu Positive
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment.
- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma
- Trial name
- NCT03418961
- Testing
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Where
- 590 sites in United States, Puerto Rico and 2 more
- Volunteers
- 491 people
- Sponsor
- SWOG Cancer Research Network
Toxic Epidermal Necrolysis, Immunotherapy
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Toxic Epidermal Necrolysis (TEN) are rare diseases that are dermatologic emergencies characterized by widespread epidermal necrosis and sloughing of skin. A hundred patients are affected each year in France.
- Conditions
- Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
- Trial name
- NET-CD38 (NCT07110662)
- Testing
- DARATUMUMAB (DARZALEX®)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Hospices Civils de Lyon
Liver Transplant Rejection, Immune System Suppression
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
Prograf and Envarsus are two different formulations of Tacrolimus which is used as an immunosuppressant in liver transplant (LT) patients.
- Trial name
- NCT05655273
- Testing
- Prograf, Envarsus
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto